Carisma Therapeutics Statistics
Share Statistics
Carisma Therapeutics has 41.75M shares outstanding. The number of shares has increased by 3.45% in one year.
| Shares Outstanding | 41.75M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 21.84M |
| Failed to Deliver (FTD) Shares | 6.26K |
| FTD / Avg. Volume | 2.36% |
Short Selling Information
The latest short interest is 568.40K, so 1.36% of the outstanding shares have been sold short.
| Short Interest | 568.40K |
| Short % of Shares Out | 1.36% |
| Short % of Float | 2.6% |
| Short Ratio (days to cover) | 2.16 |
Valuation Ratios
The PE ratio is -1.13 and the forward PE ratio is -1.09.
| PE Ratio | -1.13 |
| Forward PE | -1.09 |
| PS Ratio | 6.58 |
| Forward PS | 1.9 |
| PB Ratio | 3.7 |
| P/FCF Ratio | -1.19 |
| PEG Ratio | n/a |
Enterprise Valuation
Carisma Therapeutics Inc. has an Enterprise Value (EV) of 23.74M.
| EV / Earnings | -0.27 |
| EV / Sales | 1.59 |
| EV / EBITDA | -0.28 |
| EV / EBIT | -0.27 |
| EV / FCF | -0.29 |
Financial Position
The company has a current ratio of 5.06, with a Debt / Equity ratio of 0.
| Current Ratio | 5.06 |
| Quick Ratio | 5.06 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -3.27% and return on capital (ROIC) is -299.21%.
| Return on Equity (ROE) | -3.27% |
| Return on Assets (ROA) | -0.97% |
| Return on Capital (ROIC) | -299.21% |
| Revenue Per Employee | 139.43K |
| Profits Per Employee | -811.95K |
| Employee Count | 107 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -81.17% in the last 52 weeks. The beta is 0, so Carisma Therapeutics 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -81.17% |
| 50-Day Moving Average | 0.71 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 38.82 |
| Average Volume (20 Days) | 265.33K |
Income Statement
In the last 12 months, Carisma Therapeutics had revenue of 14.92M and earned -86.88M in profits. Earnings per share was -2.59.
| Revenue | 14.92M |
| Gross Profit | -59.21M |
| Operating Income | -88.73M |
| Net Income | -86.88M |
| EBITDA | -85.89M |
| EBIT | -88.73M |
| Earnings Per Share (EPS) | -2.59 |
Balance Sheet
The company has 77.61M in cash and 3.12M in debt, giving a net cash position of 74.48M.
| Cash & Cash Equivalents | 77.61M |
| Total Debt | 3.12M |
| Net Cash | 74.48M |
| Retained Earnings | -245.10M |
| Total Assets | 42.06M |
| Working Capital | 23.58M |
Cash Flow
In the last 12 months, operating cash flow was -81.18M and capital expenditures -1.13M, giving a free cash flow of -82.31M.
| Operating Cash Flow | -81.18M |
| Capital Expenditures | -1.13M |
| Free Cash Flow | -82.31M |
| FCF Per Share | -2.46 |
Margins
Gross margin is -396.85%, with operating and profit margins of -594.75% and -582.34%.
| Gross Margin | -396.85% |
| Operating Margin | -594.75% |
| Pretax Margin | -582.34% |
| Profit Margin | -582.34% |
| EBITDA Margin | -575.74% |
| EBIT Margin | -594.75% |
| FCF Margin | -551.71% |
Dividends & Yields
CARM pays an annual dividend of $0.36, which amounts to a dividend yield of 82.19%.
| Dividend Per Share | $0.36 |
| Dividend Yield | 82.19% |
| Dividend Growth (YoY) | -0.41% |
| Payout Ratio | -23.68% |
| Earnings Yield | -575.56% |
| FCF Yield | -433.48% |
Analyst Forecast
The average price target for CARM is $6.5, which is 1344.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.5 |
| Price Target Difference | 1344.4% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Mar 8, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Mar 8, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -13.58 |
| Piotroski F-Score | 2 |